Jason Callahan
Overview
Explore the profile of Jason Callahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Udovicich C, Callahan J, Bressel M, Ong W, Perera M, Tran B, et al.
Eur Urol Open Sci
. 2022 Oct;
44:60-68.
PMID: 36185587
Background: Prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of renal cell carcinoma (RCC). However, there remains limited evidence regarding the use of PSMA positron emission tomography/computed tomography (PET/CT)...
12.
Savas P, Lo L, Luen S, Blackley E, Callahan J, Moodie K, et al.
Cancer Discov
. 2022 Jun;
12(9):2058-2073.
PMID: 35771551
Significance: Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were...
13.
Li Z, Le Roux P, Callahan J, Hardcastle N, Hofman M, Siva S, et al.
Phys Imaging Radiat Oncol
. 2022 Apr;
22:8-12.
PMID: 35465222
Pulmonary functional imaging has demonstrated potential to improve thoracic radiotherapy. The purpose of this study was twofold: 1) to quantify ventilation/perfusion relationships in lung cancer patients using a new functional...
14.
Wong S, Raleigh J, Callahan J, Vergara I, Ftouni S, Hatzimihalis A, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-14.
PMID: 35172485
Purpose: Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by...
15.
McLean L, Cavanagh K, Hicks R, Callahan J, Xie J, Cardin A, et al.
Cancer Imaging
. 2021 Oct;
21(1):57.
PMID: 34645517
Background: The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET...
16.
Callahan J, Eager E, Rebarber R, Strawbridge E, Yuan S
Bull Math Biol
. 2021 Jun;
83(8):84.
PMID: 34142259
No abstract available.
17.
Campbell B, Callahan J, Cole-Sinclair M, MacManus M, Hofman M
Clin Nucl Med
. 2021 Mar;
46(9):e454-e457.
PMID: 33661206
As a marker of cellular proliferation, 18F-fluorothymidine (FLT) PET can detect the distribution of proliferating hematopoiesis and has an emerging role in the investigation of hematopoietic disorders. These images demonstrate...
18.
Subramaniam S, Callahan J, Bressel M, Hofman M, Mitchell C, Hendry S, et al.
J Surg Oncol
. 2021 Jan;
123(4):1081-1087.
PMID: 33444466
Background: The role of F-fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG PET/CT) in the evaluation of retroperitoneal sarcomas is poorly defined. We evaluated the correlation of maximum standardized uptake value...
19.
Bucknell N, Hardcastle N, Jackson P, Hofman M, Callahan J, Eu P, et al.
BMJ Open
. 2020 Dec;
10(12):e042465.
PMID: 33303468
Background: In the curative-intent treatment of locally advanced lung cancer, significant morbidity and mortality can result from thoracic radiation therapy. Symptomatic radiation pneumonitis occurs in one in three patients and...
20.
Weppler A, Pattison A, Bhave P, De Ieso P, Raleigh J, Hatzimihalis A, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33060145
Background: Metastatic Merkel cell carcinoma (mMCC) is an aggressive neuroendocrine malignancy of the skin with a poor prognosis. Immune checkpoint inhibitors (ICIs) have shown substantial efficacy and favorable safety in...